Browsing tag:


Nebivolol, CAS# 99200-09-6, is recognized as the brand name anti-hypertensive drug Bystolic, which is marketed by Forest Pharmaceuticals, Inc. This beta-blocker powerhouse has a patent expiration of June 2, 2015, and is projected to become a widely used generic treatment for chronic hypertension. Current dosages of Bystolic, or nebivolol,  2.5, 5, 10, and 20 milligram[…]

Read More

  Telmisartan, CAS number 144701-48-4, an Anti-Hypertensive research molecule, is also an approved TEVI API for compounding purposes, offered here from LGM Pharma. Indicated for the treatment of hypertension, telmisartan is known as the brand name Micardis, which is marketed by Boehringer Ingelheim Pharmaceuticals. As an angiotensin II receptor antagonist telmisartan is effective at preventing[…]

Read More

In a world where about a third of the adult male in the global population smokes, it’s tough not to take notice of its negative impact on the society as a whole. According to the WHO, if the smoking trends do not ease up, one in every 6 adults will die of smoking-related illness (e.g.[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service